New hope for tough colon cancer: combo therapy tested in 20 patients

This study tests whether a combination of two experimental drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and a targeted therapy can shrink tumors in adults with a specific type of advanced colorectal cancer (BRAF V600E mutation). About 20 people whose cancer has worsened after at least one prior treatment will receive the drug combo every two weeks. The goal is to see if the treatment is safe and works better than past results.